ClinicalTrials.gg
CompletedNCT00294619Updated Oct 5, 2012

Treatment of Adults With Growth Hormone Deficiency

A Phase 3 interventional study of growth hormone in Pituitary Disorders and Adult Growth Hormone Deficiency, sponsored by LG Life Sciences. Completed at 1 site in United States. Open to participants aged 23 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-10-05.

Sponsored by LG Life Sciences (part of LG Chem) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
23 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 34 studies in Pituitary Diseases with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Pituitary Diseases · United States.

Enrollment
5th of 26
147 · median 57
Started
2006
with 1 other
Phase 3
10 of 34
1 open now
Registered
5th of 34
by date

Among the 34 studies in Pituitary Diseases with a site in United States, this one is the 5th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2006, is one of 10 in phase 3, and was the 5th registered.

Pituitary Diseases

74 studies on the registry are indexed under Pituitary Diseases; 15 are open to participants now.

Browse Pituitary Diseases studies →

Open to participants now

4 of the 34 studies in Pituitary Diseases with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Pituitary Diseases studies recruiting now, 6 (50%) set no upper age limit and 3 (25%) stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 23 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Pituitary Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy and safety profile of a new weekly administered growth hormone preparation compared with placebo in adults with growth hormone deficiency.

03

Conditions studied

  • Pituitary Disorders
  • Adult Growth Hormone Deficiency

Keywords

  • Growth hormone deficiency
04

Who can participate

Ages eligible
23 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female of at least 23 years and not more than 70 years of age
  • GHD of either adult onset(AO)or Childhood onset(CO), either idiopathic or secondary to pituitary disease
  • Confirmed diagnosis of GHD defined
  • IGF-1 SDS ≤ -1 at screening
  • No exposure to rhGH within the last 6 months
  • Patients with adequate adrenal function, which is confirmed by ACTH stimulation test at screening; or Patients with known secondary hypoadrenalism on adequate replacement therapy
  • If applicable, hormone replacement therapies for any other hormone deficiencies, adequate and stable for at least 3 months before study entry
  • Women of to be using a reliable method of at the screening and be willing to use it throughout the study
  • A negative serum pregnancy test is required at screening for females of child-bearing potential.

Exclusion criteria

Exclusion Criteria:

  • History of other than cranial tumor or leukemia causing GHD or fully treated basal cell carcinoma
  • Evidence of active malignancy
  • Evidence of growth of pituitary adenoma or other intracranial tumor within the last 12 months, or patients without MRI or CT data to confirm the tumor stability within the last 12 months
  • Significant hepatic dysfunction
  • Chronic renal impairment
  • pulmonary, cardiac, hepatic, renal, or neuromuscular disease
  • Prader-Willi syndrome
  • Acute severe illness in the last 6 months
  • Benign intracranial hypertension
  • Active Cushing's syndrome within the last 12 months
  • Uncontrolled hypertension
  • Patients with overt diabetes mellitus or evidence of persistent impaired glucose tolerance
  • Severe psychiatric disease or patients who cannot understand the objective and methods of the study or patients with current alcohol abuse
  • Pregnancy or lactation
  • Known to any ingredient of the study drug
  • Inability to undergo scanning by dual-energy X ray absorptiometry (DXA) due to a body weight more than 130 kg or in situ internal or external devices known to interfere with DXA scanning
  • Weight reducing drugs or appetite suppressants
  • Anabolic steroids other than gonadal replacement therapy within 2 months before study entry
  • Methylphenidate within 2 months before study entry
  • Systemic corticosteroids other than in replacement doses within the 3 months before study entry.
  • History of non-compliance with medications, un-cooperativeness or drug abuse
  • Patients participating in another study parallel to, or within 6 months prior to study entry, or previous participation in this study
  • Patients who are not able to comply with the study protocol for any reason.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    LB03002

    Drug: growth hormone

  • Placebo comparator
    Placebo

    Drug: growth hormone

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in Fat Mass at the end of 26-week treatment from baseline

    Time frame: 26 weeks

Secondary outcomes

  1. Changes in the following parameters at the end of 26-week treatment from baseline; other body composition parameters, QoL Score, Serum IGF-I, IGFBP-3 levels & SDS, Lipid profile, waist-to-hip ratio

    Time frame: 26 weeks

07

Study locations

1 site
  • Oregon Health Sciences University
    Portland, Oregon, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2006
First posted
Feb 22, 2006
Start
Apr 2006
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Last update
Oct 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00294619
Lead sponsor
LG Life Sciences
Collaborators
BioPartners GmbH
Responsible party
Sponsor
First posted
Feb 22, 2006
Start date
Apr 2006
Primary completion
Mar 2008
Completion
Mar 2008
Last update
Oct 5, 2012

Study contacts

HJ Ji, PhD
study chair · LG Life Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Growth Hormone

Start the discussion